Bifunctional Molecules Inhibit Crystallin Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating cataracts and presbyopia, which involve the aggregation of crystallins in the eye's lens, are inadequate as they fail to effectively inhibit or reverse the progression of these age-related conditions, leading to vision loss and blindness.
Innovation Solution
The use of bifunctional molecules, such as those comprising substituted or unsubstituted amines covalently linked to polyethylene glycol molecular bristles, which act as γ-crystallin charge masking agents to prevent protein aggregation and reduce the size of existing aggregates, thereby inhibiting or reversing cataract formation and presbyopia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for cataracts and presbyopia are used, then surgery is required to remove the lens, but this results in loss of natural accommodation and requires implantation of artificial lenses
Solution Approach 1:
The patent uses charge masking agents as intermediary molecules that bind to crystallin proteins and mask their surface charges, preventing aggregation without requiring surgical removal of the lens. This mediator approach allows non-surgical treatment while preserving the natural lens structure and accommodation function
Solution Approach 2:
The invention changes the electrostatic parameters of crystallin proteins by masking their surface charges with charged molecules. This parameter change prevents the electrostatic attraction that leads to aggregation, thereby inhibiting cataract formation and presbyopia progression without surgery
2Object-affected harmful factors
If crystallins aggregate in the lens, then cataract formation and presbyopia occur, but current treatments cannot effectively inhibit or reverse this aggregation
Solution Approach 1:
The patent converts the harmful electrostatic attraction between crystallins into a beneficial effect by using charged masking agents that exploit electrostatic interactions to prevent aggregation. The same electrostatic forces that cause harm are harnessed in reverse to provide protection
Solution Approach 2:
The charge masking agents work by self-assembling with crystallin proteins through electrostatic attraction, automatically masking the charged surfaces without requiring external intervention. The system serves itself by using the inherent electrostatic properties of the proteins to drive the protective mechanism
3Quantity of substance
If α-crystallin concentration decreases with age, then it becomes incorporated into aggregates, but this process cannot be effectively reversed
Solution Approach 1:
The patent introduces charge masking agents as intermediaries that bind to crystallins and prevent their incorporation into aggregates. This intermediary approach maintains α-crystallin in its soluble, functional state by blocking the aggregation pathway
Solution Approach 2:
The invention changes the solubility parameters of crystallins by masking their surface charges, thereby preventing the phase transition from soluble to insoluble aggregate form. This parameter change maintains the beneficial soluble state of α-crystallin
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These bifunctional molecules effectively disaggregate crystallin aggregates, reducing the progression and severity of cataracts and presbyopia, offering a potential non-surgical treatment for these conditions.
Implementation Method 1
bifunctional molecule comprising a substituted or unsubstituted amine, succinimide, carboxylic acid, isocyanate, isothiocyanate, sulfonyl chloride, aldehyde, carbodiimide, acyl azide, anhydride, fluorobenzene, carbonate, N-hydroxysuccinimide ester, imidoester, epoxide or fluorophenyl ester; covalently linked to a molecular bristle
Data Source
AI summary
Described herein are methods of inhibiting or reversing the progression of cataract formation or presbyopia in an eye by administering a bifunctional molecule comprising a substituted or unsubstituted amine, succinimide, carboxylic acid, isocyanate, isothiocyanate, sulfonyl chloride, aldehyde, carbodiimide, acyl azide, anhydride, fluorobenzene, carbonate, N-hydroxysuccinimide ester, imidoester, epoxide or fluorophenyl ester covalently linked to a molecular bristle. Both presbyopia and cataracts are caused by aggregation of the soluble crystalline lens proteins called the crystallins.